Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kiniksa Pharmaceuticals International's quarterly market cap
stayed the same
from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN0 Mil) but then
increased
from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN57,852 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kiniksa Pharmaceuticals International's Enterprise Value for Today is MXN78,128 Mil.
Kiniksa Pharmaceuticals International (MEX:KNSAN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kiniksa Pharmaceuticals International Market Cap Related Terms
Kiniksa Pharmaceuticals International Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Market Cap Chart
MEX:KNSAN vs INDV, AMRX, RGC: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Market Cap distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's Market Cap falls into.
Kiniksa Pharmaceuticals International Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (MEX:KNSAN) has a Market Cap of MXN86,170 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kiniksa Pharmaceuticals International and its competitors. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #80 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Kiniksa Pharmaceuticals International's Market Cap too high?
Kiniksa Pharmaceuticals International's current Market Cap is MXN86,170 Mil. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #80 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Market Cap compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #80 out of 1024 companies for Market Cap. This places Kiniksa Pharmaceuticals International in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 225.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 225.62, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median Market Cap is 225.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current Market Cap is MXN86,170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Kiniksa Pharmaceuticals International (MEX:KNSAN) has a current Market Cap of MXN86,170 Mil. The stock's GF Value™ is MXN601.54, compared to a current price of MXN754.37 — trading 25.4% above its estimated fair value. The current Market Cap is MXN86,170 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (MEX:KNSAN), the current Market Cap is MXN86,170 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of MXN754.37 is trading 25.4% above its estimated GF Value™ of MXN601.54.
Key valuation signals for MEX:KNSAN:
Market Cap: MXN86,170 Mil
GF Value™: MXN601.54 vs. price of MXN754.37 (25.4% above fair value)
No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for MEX:KNSAN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KNSAN has been successfully added to your 
